LAI Zongqiang,LI Jun,SHANG Yongguang.Anti-infection treatment and pharmaceutical care for a patient with severe pneumonia caused by Chlamydia psittaci[J].ZHONGGUO YAOFANG,2024,35(02):242-246.
LAI Zongqiang,LI Jun,SHANG Yongguang.Anti-infection treatment and pharmaceutical care for a patient with severe pneumonia caused by Chlamydia psittaci[J].ZHONGGUO YAOFANG,2024,35(02):242-246. DOI: 10.6039/j.issn.1001-0408.2024.02.21.
Anti-infection treatment and pharmaceutical care for a patient with severe pneumonia caused by Chlamydia psittaci
To provide ideas and reference for the anti-infection treatment and pharmaceutical care for severe pneumonia caused by
Chlamydia psittaci
.
METHODS
2
Clinical pharmacists participated in the whole process of the treatment for a patient with
C. psittaci
-induced severe pneumonia. According to the patient’s medical history, clinical symptoms and test results, clinical pharmacists assisted the physician to dynamically adjust the anti-infective scheme; for
C. psittaci
infection, the patient was treated with tigecycline combined with azithromyci
n successively, and other infection therapy plans were dynamically adjusted according to the results of pathogen examination. During the treatment, the patient suffered from suspicious adverse drug reactions such as prolonged QTc interval, elevated lipase and amylase; the clinical pharmacists conducted pharmaceutical care and put forward reasonable suggestions.
RESULTS
2
The physician adopted the pharmacists’ suggestion, and the patient was discharged after treatment.
CONCLUSIONS
2
For the treatment of severe pneumonia caused by
C. psittaci
, the characteristics of patients, drugs and pathogens should be taken into account to develop individualized anti-infective treatment. Tetracyclines and macrolides have a definite effect on
C. psittaci
infection, but attention should be paid to the possible ADR caused by drugs in clinical application.
关键词
Keywords
references
ZHANG Z J , ZHOU H , CAO H E , et al . Human-to-human transmission of Chlamydia psittaci in China,2020:an epidemiological and aetiological investigation [J ] . Lancet Microbe , 2022 , 3 ( 7 ): e512 - e520 .
HOGERWERF L , GIER B D , BAAN B , et al . Chlamydia psittaci (psittacosis)as a cause of community-acquired pneumonia:a systematic review and meta-analysis [J ] . Epidemiol Infect , 2017 , 145 ( 15 ): 3096 - 3105 .
WU X D , LI Y Y , ZHANG M , et al . Etiology of severe community-acquired pneumonia in adults based on metagenomic next-generation sequencing:a prospective multicenter study [J ] . Infect Dis Ther , 2020 , 9 ( 4 ): 1003 - 1015 .
GUO Y , ZHOU Y , DU X H . One case report of severe pneumonia caused by Chlamydia psittaci [J ] . Chin J Infect Chemother , 2021 , 21 ( 2 ): 211 - 213 .
LIU J M , GAO Y . Tigecycline in the treatment of severe pneumonia caused by Chlamydia psittaci :a case report and literature review [J ] . Front Med , 2022 , 9 : 1040441 .
LI J , ZHU D Q . The pharmaceutical care of a multidrug-resistant bacterial infection patient with tigecycline-induced hypofibrinogenemia [J ] . China Pharm , 2023 , 34 ( 8 ): 1010 - 1013,1024 .
TANG X F , YAN Y D . Clinical application,drug resistance and adverse effects of azithromycin [J ] . Int J Pediatr , 2021 , 48 ( 2 ): 104 - 107 .
LU Z M , HOU M L , LI D D , et al . Azithromycin combined with doxycycline in non-gonococcal urethritis [J ] . Exp Ther Med , 2020 , 20 ( 4 ): 3887 - 3894 .
KONG C Y , ZHU J , LU J J , et al . Clinical characteristics of Chlamydia psittaci pneumonia [J ] . Chin Med J , 2021 , 134 ( 3 ): 353 - 355 .
LIU C C , LIU Y Q . Drug use analysis of two patients with QT interval prolongation caused by drugs [J ] . Cent South Pharm , 2023 , 21 ( 10 ): 2813 - 2816 .
TISDALE J E , CHUNG M K , CAMPBELL K B , et al . Drug-induced arrhythmias:a scientific statement from the American Heart Association [J ] . Circulation , 2020 , 142 ( 15 ): e214 - e233 .
TISDALE J E , JAYNES H A , KINGERY J R , et al . Develop-ment and validation of a risk score to predict QT interval prolongation in hospitalized patients [J ] . Circ Cardiovasc Qual Outcomes , 2013 , 6 ( 4 ): 479 - 487 .
National Medical Products Administration . Notice of the National Medical Products Administration on issuing gui-ding principles for collection and reporting of adverse drug reactions in individual cases [EB/OL ] .( 2018-12-19 )[ 2023-08-02 ] . https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20181221-172901438.html https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20181221-172901438.html .
ZHOU X P , REN J L , LU R Q , et al . Domestic and foreign literature of adverse drug reactions induced by tigecycline [J ] . Eval Anal Drug Use Hosp China , 2023 , 23 ( 2 ): 241 - 244 .
Individualized treatment and pharmaceutical care for breast cancer complicated with chronic kidney disease
Anticoagulation therapy analysis and pharmaceutical care for a breast cancer patient with pulmonary thromboembolism accompanied by multiple comorbidities
Antithrombotic therapy and pharmaceutical care of a child with purpura nephritis complicated with lower extremity deep venous thrombosis
Pharmaceutical care for a patient with diabetes complicated with suspected hyperlipidemia induced by immunosuppressive agents after liver transplantation
Pharmacy practice of clinical pharmacists involved in the treatment of a case of bullous pemphigoid and pulmonary aspergillosis combined with disseminated Nocardia farcinica infection
Related Author
ZHANG Ming
YU Lu
WU Xudong
CHENG Qijian
HUO Meng
LIN Jiayuan
LI Boxia
LIU Weiting
Related Institution
Dept. of Internal Medicine, Zhonggongmiao Community Hospital of Ningbo Yinzhou District No.2 Hospital Medical Community
Dept. of Clinical Pharmacy, Ningbo Yinzhou District No.2 Hospital
Dept. of Pulmonary & Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Dept. of Pharmacy, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Dept. of Pharmacy, the First Affiliated Hospital of Wenzhou Medical University